Merck won't change endpoint in new Vytorin trial

Merck resisted a steering committee's recommendation to change the primary endpoint in a new clinical trial of its cholesterol drug Vytorin in chronic kidney patients, three years after an endpoint change in the Enhance trial of that drug drew a firestorm of criticism. Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.